Table 4.
Determinants of oral anticoagulation prescribed within the month following cohort entry
| Determinants | OAC |
Warfarin |
DOACs |
|||
|---|---|---|---|---|---|---|
| Crude | Adjusted | Crude | Adjusted | Crude | Adjusted | |
| Age, y, ≥ 65 vs < 65 | 1.72 (1.40–2.12) | 1.29 (0.99–1.67) | 1.59 (1.25–2.01) | 1.18 (0.88–1.57) | 1.27 (0.99–1.62) | 1.18 (0.87–1.62) |
| Female vs male | 1.08 (0.94–1.25) | 0.91 (0.78–1.08) | 1.11 (0.95–1.29) | 0.98 (0.83–1.16) | 0.98 (0.83–1.15) | 0.88 (0.73–1.07) |
| CHADS2 score ≥ 3 vs < 3 | 1.74 (1.48–2.04) | 1.67 (1.33–2.09) | 1.84 (1.52–2.22) | 1.60 (1.25–2.05) | 1.07 (0.89–1.29) | 1.12 (0.86–1.46) |
| HAS-BLED score ≥ 3 vs < 3 | 0.91 (0.79–1.05) | 0.85 (0.70–1.03) | 1.15 (0.99–1.34) | 1.00 (0.82–1.23) | 0.75 (0.64–0.87) | 0.84 (0.67–1.04) |
| Charlson Comorbidity Index ≥ 4 vs < 4 | 1.33 (1.16–1.53) | 1.28 (1.08–1.52) | 1.40 (1.20–1.62) | 1.18 (0.99–1.41) | 1.02 (0.87–1.20) | 1.17 (0.96–1.43) |
| Previous stroke (yes vs no) | 1.43 (1.16–1.75) | 1.33 (1.05–1.68) | 1.39 (1.12–1.71) | 1.32 (1.05–1.66) | 1.09 (0.87–1.38) | 1.04 (0.80–1.37) |
| Prior major bleeding (yes vs no) | 0.87 (0.76–0.99) | 0.81 (0.68–0.96) | 1.03 (0.89–1.20) | 0.88 (0.74–1.06) | 0.80 (0.68–0.95) | 0.87 (0.71–1.07) |
| Chronic renal failure (eGFR ≤ 30 mL/min) vs ≥ 30 | 0.93 (0.71–1.23) | 0.96 (0.71–1.29) | 1.53 (1.16–2.02) | 1.35 (0.99–1.84) | 0.43 (0.29–0.64) | 0.51 (0.33–0.79) |
| Peripheral artery disease (yes vs no) | 1.03 (0.89–1.18) | 0.90 (0.76–1.06) | 1.11 (0.95–1.29) | 0.99 (0.84–1.18) | 0.90 (0.76–1.06) | 0.84 (0.69–1.03) |
| Liver disease (yes vs no) | 0.63 (0.41–0.95) | 0.65 (0.41–1.03) | 0.68 (0.42–1.10) | 0.66 (0.39–1.09) | 0.80 (0.48–1.34) | 0.94 (0.54–1.63) |
| Medication use within the 2weeks prior to cohort entry | ||||||
| DOAC | 6.27 (4.82–8.15) | 7.79 (5.94–10.23) | 0.60 (0.48–0.75) | 0.71 (0.56–0.89) | 9.22 (7.50–11.35) | 9.04 (7.29–11.21) |
| Warfarin | 4.42 (3.27–5.97) | 6.18 (4.52–8.45) | 8.19 (6.26–10.71) | 8.14 (6.17–10.75) | 0.24 (0.16–0.36) | 0.37 (0.24–0.57) |
| Baseline ASA use at cohort entry (excluding antiplatelet) | 0.54 (0.46–0.62) | 0.49 (0.41–0.58) | 0.68 (0.58–0.80) | 0.61 (0.51–0.74) | 0.61 (0.51–0.74) | 0.60 (0.48–0.75) |
| Baseline P2Y12 inhibitor use | 0.44 (0.35–0.55) | 0.54 (0.42–0.70) | 0.56 (0.43–0.73) | 0.62 (0.46–0.83) | 0.58 (0.43–0.77) | 0.72 (0.52–1.00) |
Values are odds ratio (95% confidence interval).
ASA, acetylsalicylic acid; CHADS2, Congestive Heart Failure, Hypertension, Age ≥ 75, Diabetes, and Prior Stroke/Transient Ischemic Attack (doubled); DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly (> 65 Years), Drugs/Alcohol Concomitantly; OAC, oral anticoagulation.